Aaron C Miller

US Patent:

41810244, Jan 1, 1980

Filed:

Aug 15, 1978

Appl. No.:

5/933949

Inventors:

John Leak - Swarthmore PA
Aaron Miller - Aston PA

Assignee:

The Boeing Company - Seattle WA

International Classification:

G01N 2900

US Classification:

73660

Abstract:

What follows is a description of a system for detecting rotor system related vibration in a helicopter. The vibration detecting system comprises three essential units: a sensing unit or device; a control unit; and a model module. Actually, any number of sensing units can be utilized depending upon the number of locations at which the vibration is to be monitored. The sensing unit generates a signal indicative of the rotor system related vibration and delivers this signal to the control unit which operates on the generated signal and produces an output signal within a selected frequency and amplitude range. The output signal is then displayed, for example, on a scale meter. The model module is adaptable for compatibility with the dynamic rotor system of a given helicopter model and is utilized as such to set the limits of the selected frequency and amplitude range of the control unit. The model module is readily connected to and removed from the housing of the control unit.

US Patent:

20220315556, Oct 6, 2022

Filed:

May 10, 2019

Appl. No.:

17/054491

Inventors:

- Brentford, GB
Mui Cheung - King of Prussia PA, US
Michael P. Demartino - Collegeville PA, US
Huiping Amy Guan - Acton MA, US
Yan Hu - Shanghai, CN
Aaron Bayne Miller - Research Triangle Park NC, US
Donghui Qin - Malvern PA, US
Chengde Wu - Shanghai, CN
Zhiliu Zhang - Shanghai, CN
Xiaojuan Lin - Shanghai, CN

Assignee:

Glaxosmithkline Intellectual Property Development Limited - Brentford

International Classification:

C07D 401/14
A61P 11/00
C07D 401/12
C07D 211/26
C07D 487/08

Abstract:

This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.